A key theme emerging from FDA complete response letters since 2018 is that data system validation is lacking in the ...
Earlier this week, contract development and manufacturing organization (CDMO) Cellares announced its partnership with ...
BioProcess International learned about how advanced therapy developers and manufacturers are adapting to changing ...
Biopharmaceutical organizations are seeking out ways to increase predictability in clonal material generated during cell line ...
BPI Contributor Sidharth Ananthanarayan ...
The FDA’s May 2026 guidance on cell and gene therapies provides for CMC flexibilities while insisting on quality and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results